Veracyte (VCYT) grants CEO Marc Stapley 92,099 RSUs vesting from 2027

Rhea-AI Filing Summary

Stapley Marc reported acquisition or exercise transactions in this Form 4 filing.

VERACYTE, INC. reported that Chief Executive Officer Marc Stapley received a grant of 92,099 shares of common stock on March 6, 2026, in the form of restricted stock units. These RSUs vest 25% on March 2, 2027 and 1/16 each quarter thereafter, subject to his continued employment. Following this award, he directly holds 449,653 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stapley Marc

(Last) (First) (Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		A(1)		92,099	A	$0	449,653	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units awarded on March 6, 2026 vest 25% on March 2, 2027 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.

Remarks:

	/s/ Jonathan Wygant as attorney-in-fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Veracyte (VCYT) CEO Marc Stapley report on this Form 4?

Marc Stapley reported receiving a grant of 92,099 shares of Veracyte common stock as restricted stock units. The grant was made on March 6, 2026 and represents equity compensation, not an open-market stock purchase or sale.

How many Veracyte (VCYT) shares were granted to the CEO in this filing?

The CEO was granted 92,099 restricted stock units representing Veracyte common shares. These units carry no cash exercise price and are designed to convert into shares over time as they vest, aligning executive compensation with long-term company performance and continued employment.

What is the vesting schedule for Marc Stapley’s Veracyte (VCYT) RSU award?

The restricted stock units vest 25% on March 2, 2027, then 1/16 of the award each quarter thereafter. Each vesting date requires Marc Stapley to remain employed, so the grant functions as a multi-year retention and incentive tool for Veracyte’s chief executive officer.

How many Veracyte (VCYT) shares does the CEO hold after this RSU grant?

After the reported RSU grant, Marc Stapley directly holds 449,653 Veracyte common shares. This figure reflects his post-transaction position reported in the Form 4 and highlights a substantial ongoing equity stake tied to the company’s future performance and share price.

Was this Veracyte (VCYT) Form 4 an open-market stock purchase or sale?

No, the Form 4 shows a compensation-related acquisition coded as a grant or award, not an open-market trade. The 92,099 units were awarded at a reported price of zero, vesting over time rather than being bought or sold on a stock exchange.